Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 4.72
ANAC's Cash to Debt is ranked higher than
67% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 68.42 vs. ANAC: 4.72 )
ANAC' s 10-Year Cash to Debt Range
Min: 0.48   Max: No Debt
Current: 4.72

Equity to Asset 0.67
ANAC's Equity to Asset is ranked higher than
74% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. ANAC: 0.67 )
ANAC' s 10-Year Equity to Asset Range
Min: -11.16   Max: 0.71
Current: 0.67

-11.16
0.71
Interest Coverage 22.84
ANAC's Interest Coverage is ranked higher than
56% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ANAC: 22.84 )
ANAC' s 10-Year Interest Coverage Range
Min: 22.84   Max: 22.84
Current: 22.84

F-Score: 7
Z-Score: 11.09
M-Score: 2.47
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 537.02
ANAC's Operating margin (%) is ranked higher than
100% of the 794 Companies
in the Global Biotechnology industry.

( Industry Median: -68.50 vs. ANAC: 537.02 )
ANAC' s 10-Year Operating margin (%) Range
Min: -15647.66   Max: 537.02
Current: 537.02

-15647.66
537.02
Net-margin (%) 492.02
ANAC's Net-margin (%) is ranked higher than
99% of the 794 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. ANAC: 492.02 )
ANAC' s 10-Year Net-margin (%) Range
Min: -15368.22   Max: 492.02
Current: 492.02

-15368.22
492.02
ROE (%) 69.80
ANAC's ROE (%) is ranked higher than
99% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. ANAC: 69.80 )
ANAC' s 10-Year ROE (%) Range
Min: -1165.81   Max: 69.8
Current: 69.8

-1165.81
69.8
ROA (%) 49.23
ANAC's ROA (%) is ranked higher than
99% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -17.51 vs. ANAC: 49.23 )
ANAC' s 10-Year ROA (%) Range
Min: -300.58   Max: 49.23
Current: 49.23

-300.58
49.23
ROC (Joel Greenblatt) (%) 6345.47
ANAC's ROC (Joel Greenblatt) (%) is ranked higher than
100% of the 876 Companies
in the Global Biotechnology industry.

( Industry Median: -201.33 vs. ANAC: 6345.47 )
ANAC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4368.24   Max: 6345.47
Current: 6345.47

-4368.24
6345.47
Revenue Growth (%) -34.10
ANAC's Revenue Growth (%) is ranked higher than
62% of the 638 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. ANAC: -34.10 )
ANAC' s 10-Year Revenue Growth (%) Range
Min: -70.5   Max: 467.9
Current: -34.1

-70.5
467.9
» ANAC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ANAC Guru Trades in Q3 2013

Steven Cohen 248,478 sh (New)
» More
Q4 2013

ANAC Guru Trades in Q4 2013

Jim Simons 105,800 sh (New)
Steven Cohen 604,900 sh (+143.44%)
» More
Q1 2014

ANAC Guru Trades in Q1 2014

Steven Cohen Sold Out
Jim Simons 32,700 sh (-69.09%)
» More
Q2 2014

ANAC Guru Trades in Q2 2014

Jim Simons 207,578 sh (+534.8%)
» More
» Details

Insider Trades

Latest Guru Trades with ANAC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-03-31 Sold Out 0.0017%$3.15 - $6.52 $ 21.11389%0
Jean-Marie Eveillard 2012-12-31 New Buy$4.6 - $6.81 $ 21.11280%92390
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 13.30
ANAC's P/E(ttm) is ranked higher than
98% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ANAC: 13.30 )
ANAC' s 10-Year P/E(ttm) Range
Min: 8.48   Max: 13.32
Current: 13.3

8.48
13.32
P/B 7.90
ANAC's P/B is ranked higher than
53% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. ANAC: 7.90 )
ANAC' s 10-Year P/B Range
Min: 2.44   Max: 177.5
Current: 7.9

2.44
177.5
P/S 46.73
ANAC's P/S is ranked lower than
61% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 17.18 vs. ANAC: 46.73 )
ANAC' s 10-Year P/S Range
Min: 0.3   Max: 49.36
Current: 46.73

0.3
49.36
PFCF 12.70
ANAC's PFCF is ranked higher than
98% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ANAC: 12.70 )
ANAC' s 10-Year PFCF Range
Min: 0.67   Max: 12.78
Current: 12.7

0.67
12.78
EV-to-EBIT 8.47
ANAC's EV-to-EBIT is ranked higher than
98% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ANAC: 8.47 )
ANAC' s 10-Year EV-to-EBIT Range
Min: 5.3   Max: 9
Current: 8.47

5.3
9
Current Ratio 7.58
ANAC's Current Ratio is ranked higher than
85% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.97 vs. ANAC: 7.58 )
ANAC' s 10-Year Current Ratio Range
Min: 0.4   Max: 9.58
Current: 7.58

0.4
9.58
Quick Ratio 7.58
ANAC's Quick Ratio is ranked higher than
86% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. ANAC: 7.58 )
ANAC' s 10-Year Quick Ratio Range
Min: 0.4   Max: 9.58
Current: 7.58

0.4
9.58

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.80
ANAC's Price/Net Cash is ranked higher than
75% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ANAC: 10.80 )
ANAC' s 10-Year Price/Net Cash Range
Min: 2.95   Max: 162.25
Current: 10.8

2.95
162.25
Price/Net Current Asset Value 10.50
ANAC's Price/Net Current Asset Value is ranked higher than
72% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 169.30 vs. ANAC: 10.50 )
ANAC' s 10-Year Price/Net Current Asset Value Range
Min: 2.9   Max: 81.13
Current: 10.5

2.9
81.13
Price/Tangible Book 8.30
ANAC's Price/Tangible Book is ranked higher than
57% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 8.60 vs. ANAC: 8.30 )
ANAC' s 10-Year Price/Tangible Book Range
Min: 2.67   Max: 93.17
Current: 8.3

2.67
93.17
Price/Median PS Value 3.50
ANAC's Price/Median PS Value is ranked lower than
54% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. ANAC: 3.50 )
ANAC' s 10-Year Price/Median PS Value Range
Min: 0.03   Max: 3.44
Current: 3.5

0.03
3.44
Price/Graham Number 2.00
ANAC's Price/Graham Number is ranked higher than
94% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ANAC: 2.00 )
ANAC' s 10-Year Price/Graham Number Range
Min: 1.42   Max: 1.94
Current: 2

1.42
1.94
Earnings Yield (Greenblatt) 11.30
ANAC's Earnings Yield (Greenblatt) is ranked higher than
76% of the 463 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. ANAC: 11.30 )
ANAC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 11.1   Max: 18.9
Current: 11.3

11.1
18.9
Forward Rate of Return (Yacktman) -45.27
ANAC's Forward Rate of Return (Yacktman) is ranked higher than
62% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. ANAC: -45.27 )
ANAC' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -80.2   Max: -27.6
Current: -45.27

-80.2
-27.6

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:44A.Germany
Anacor Pharmaceuticals, Inc. was incorporated in Delaware in December 2000 and began business operations in March 2002. It was formerly known as AnaMax, Inc. and changed its name to Anacor Pharmaceuticals, Inc. in 2002. The Company engages in the discovery, development and commercialization of novel small molecule therapeutics derived from its novel boron chemistry platform. Its lead candidates aim to treat onychomycosis, psoriasis, and hospital-acquired bacterial infections. Its lead product candidates include tavaborole, an antifungal product candidate in Phase III clinical development for the treatment of onychomycosis; and AN2728, an anti-inflammatory product candidate that completed Phase II clinical trials for the treatment of atopic dermatitis and psoriasis. It also engages in developing GSK2251052, or GSK '052, a systemic antibiotic product candidate in Phase II clinical development for the treatment of infections caused by Gram-negative bacteria; AN8194 for the treatment of an animal health indication; and AN5568, a Phase I human clinical trial product targeting human African trypanosomiasis. The Company's clinical pipeline also includes AN2718, a topical antifungal product candidate, which is in Phase I clinical trials for the treatment of onychomycosis and fungal infections of the skin; and AN2898, a topical anti-inflammatory product candidate in the Phase IIa clinical trials for the treatment of atopic dermatitis and psoriasis. It has research, development, and collaboration agreements with GlaxoSmithKline LLC; Eli Lilly and Company; Medicis Pharmaceutical Corporation; and Medicines for Malaria Ventures.
» More Articles for ANAC

Headlines

Articles On GuruFocus.com
Paulson Bets Again On Mallinckrodt Aug 07 2014 
3 Great Dividend Stocks at All-Time Highs Aug 19 2013 
Weekly CFO Buys Highlight Aug 19 2013 
Senior Vice President and CFO of Anacor Pharmaceuticals Inc. Geoffrey Parker Bought 43,046 Shares Jun 20 2013 
This Week's Top Insider Buys Jun 19 2013 
comment on ANAC Mar 15 2013 
Weekly CFO Buys Highlight: SSP, BMTI, POL, ANAC, CYTX Mar 26 2012 
Weekly CFO Buys Highlight: GSVC, SHO, YAVY, CMCSA, ANAC May 16 2011 


More From Other Websites
ANACOR PHARMACEUTICALS, INC. Financials Aug 19 2014
Rigel's R348 Fails in Phase II Study, Shares Down 13.6% Aug 14 2014
Anacor (ANAC) Shares March Higher, Can It Continue? Aug 13 2014
AVEO Pharmaceuticals Posts Narrower-than-Expected Q2 Loss Aug 13 2014
Anacor's Q2 Loss Narrower than Expected, Kerydin in Focus Aug 12 2014
Salix Pharmaceuticals Beats on Q2 Earnings, Cuts Guidance Aug 12 2014
ARIAD Falls on Wider-than-Expected Loss, Revenues Miss Aug 11 2014
ANACOR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Aug 11 2014
ANACOR PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 07 2014
Anacor Pharmaceuticals Reports Second Quarter 2014 Financial Results Aug 07 2014
Anacor Pharmaceuticals to Present at Upcoming Investor Conferences Aug 07 2014
Anacor Pharmaceuticals to Present at Upcoming Investor Conferences Aug 07 2014
Q2 2014 Anacor Pharmaceuticals Inc Earnings Release - After Market Close Aug 07 2014
Should You Buy Anacor Pharmaceuticals (ANAC) Ahead of Earnings? Aug 06 2014
Anacor Pharmaceuticals Announces Second Quarter 2014 Financial Results Conference Call and Webcast Aug 01 2014
Anacor Pharmaceuticals Announces Second Quarter 2014 Financial Results Conference Call and Webcast Aug 01 2014
Anacor's Kerydin to Be Commercialized by Sandoz in the U.S. Jul 22 2014
Anacor Pharmaceuticals, Inc. (ANAC) in Focus: Stock Surges 6.76% Jul 22 2014
Anacor Pharmaceuticals and Sandoz Enter Into an Agreement for the Commercialization of KERYDIN in... Jul 21 2014
ANACOR PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jul 21 2014
Anacor Pharmaceuticals and Sandoz Enter Into an Agreement for the Commercialization of KERYDIN in... Jul 21 2014
Anacor's Kerydin Gets FDA Nod for Onychomycosis Jul 09 2014
ANACOR PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 08 2014
FDA Approves Anacor Pharmaceuticals' KERYDIN™ (Tavaborole) Topical Solution, 5% for the Treatment... Jul 08 2014
FDA Approves Anacor Pharmaceuticals’ KERYDIN™ (Tavaborole) Topical Solution, 5% for the... Jul 08 2014
FDA Oks Valeant toenail fungus treatment Jublia Jun 09 2014
Anacor Pharmaceuticals Appoints Paul L. Berns as Chief Executive Officer Mar 19 2014
Anacor Pharmaceuticals Reports 2013 Fourth Quarter and Year-End Financial Results Mar 13 2014
Anacor Pharmaceuticals Announces Appointment of Vince Ippolito as Chief Commercial Officer Mar 10 2014
Anacor Pharmaceuticals Announces 2013 Fourth Quarter and Year End Financial Results Conference Call... Mar 06 2014
Anacor Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting With FDA for the... Feb 27 2014
Anacor Pharmaceuticals to Present at the Cowen & Company 34th Annual Health Care Conference Feb 26 2014
Anacor Pharmaceuticals Announces Publication of Article Describing Boron-Containing Compounds and... Feb 13 2014
Anacor Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference Nov 27 2013
Anacor Pharmaceuticals Announces Positive Preliminary Results from AN2728 MUSE Study in Pediatric... Nov 12 2013
Anacor Pharmaceuticals Reports Third Quarter 2013 Financial Results Nov 07 2013
Anacor Pharmaceuticals Announces Third Quarter 2013 Financial Results Conference Call and Webcast Nov 04 2013
Anacor Pharmaceuticals Announces Settlement Agreement with Valeant Pharmaceuticals Oct 28 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide